Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03098758|
Recruitment Status : Recruiting
First Posted : April 4, 2017
Last Update Posted : July 24, 2019
Gastric carcinoma is a disease with a high mortality. Peritoneal washing cytology has a recognized prognostic utility. However sensibility of this study is not appropriate. Studies with PCR (polymerase chain retrotranscription) can increase sensibility and accurate staging information.
Objective: To analyze the sensibility and specificity of the expression of CK20, CEA and Ber-EP4 with PCR technique in peritoneal washings of advanced gastric carcinoma without clinical evidence of peritoneal carcinomatosis.
Methodology: Retrotranscription analysis (RT-PCR) and quantitative PCR (qPCR) of CK20, CEA and Ber-EP4 in peritoneal washing. Test the feasibility of qPCR with this new marker (Ber-EP4). Comparison of the results with data obtained with conventional cytology. Study of peritoneal recurrence.
|Condition or disease|
|Gastric Cancer Polymerase Chain Reaction|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Pilot Study of Comparative Molecular Analysis CK20, CEA and BER-EP4 in Peritoneal Washing Citology for Locally Advanced Gastric Cancer and Their Ability to Predict Peritoneal Dissemination|
|Actual Study Start Date :||May 8, 2017|
|Estimated Primary Completion Date :||April 2020|
|Estimated Study Completion Date :||April 2020|
- specific markers in peritoneal cells [ Time Frame: during surgical intervention ]Detection of CK20, CEA and BER-EP4 by PCR technique in peritoneal washing of advanced gastric cancer
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03098758
|Contact: Alexis Luna, MD PhD||0034937231010 ext 21458||Aluna@tauli.cat|
|Parc Tauli Hospital Universitari||Recruiting|
|Sabadell, Barcelona, Spain, 08208|
|Principal Investigator:||Alexis Luna, MD PhD||Corporación Parc Taulí|